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ABSTRACT
Introduction: The purpose of this project was
to evaluate the role of MR antagonists as an
adjunct in patients with neovascular age-related
macular degeneration (AMD) who have chronic
subretinal fluid.
Methods: Inclusion criteria were patients with a
diagnosis of neovascular AMD, who had
completed at least six anti-VEGF injections,
and had persistent subretinal fluid (SRF) on
optical coherence tomography (OCT).
Treatment with oral eplerenone was initiated
and dose titrated according to protocol.
Results: 23 patients were included in the study
(mean age = 54.6, 52.2% female, 47.8% male).
13 of the 23 patients had predominantly
chronic subretinal fluid without large PEDs. In
this subgroup, mean initial central macular
thickness (CMT) prior to starting oral
eplerenone was 305.3 lm, and mean injection
interval was 40.25 days. Mean final CMT after at
least 3 months of adjunctive eplerenone
treatment was 240.6 lm and mean injection
interval with adjunctive treatment was
54.61 days. Mean extension of the injection
interval after commencing oral eplerenone was
14.36 days.
Conclusions: These findings suggest oral MR
antagonists may have a role as an adjunctive
treatment in neovascular AMD, and may be
particularly useful in dehydration of the
subretinal space in the setting of chronic
subretinal fluid. Further research is needed in
randomized controlled trials to elucidate the
precise role of oral MR antagonists in
neovascular AMD.
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INTRODUCTION
Overactivation of mineralocorticoid receptor
pathways in choroidal vessels have been noted
in experimental models of central serous
chorioretinopathy (CSCR) [1].
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Mineralocorticoid antagonism through oral
agents (eplerenone and spironolactone) have
subsequently demonstrated success in
treatment of persistent CSCR [2, 3]. CSCR can
have a relapsing or persistent course that is
marked by chronic subretinal fluid and can lead
to significant visual morbidity [4].
Chronic subretinal fluid is also encountered
in select cases of persistent neovascular
age-related macular degeneration (AMD) that is
refractory to anti-VEGF treatment. There are
multiple treatment options that have been
explored in this setting; these have
demonstrated varying levels of success.
Alternating one’s choice of anti-VEGF
treatment can lead to an improved treatment
response in selected cases [5]. A subset of patients
appear to have persistent subretinal fluid in the
absence of persistent intraretinal fluid, and this
has been described as a ‘‘secondary sick RPE
syndrome’’ [6]. Photodynamic therapy (PDT) has
been described as successful in some of these
cases, even in the absence of any identification
of polypoidal choroidal vasculopathy or true
CSCR [6].
No satisfactory treatment modality has been
described for these cases of neovascular AMD
refractory to anti-VEGF treatment [7]. The
purpose of this study was to evaluate the
efficacy of eplerenone as an adjunctive
treatment in cases of neovascular AMD with
refractory subretinal fluid.
METHODS
This was a retrospective study conducted at a
single center with two retinal surgeons with IRB
approval. Patients were included in the study if
they had a previous diagnosis of neovascular
AMD, had completed at least six anti-VEGF
injections (bevacizumab, ranibizumab, and/or
aflibercept), and had persistent subretinal fluid
in the absence of intraretinal fluid on optical
coherence tomography (OCT) imaging. All
patients underwent repeat imaging with
fluorescein angiography and indocyanine
green angiography to rule out polypoidal
choroidal vasculopathy, classic central serous
retinopathy, or other pathology as causes of
persistent subretinal fluid. Patients were then
started on oral eplerenone 25 mg PO BID,
initially maintaining their same injection
interval. If subretinal fluid persisted, the
medication dose was increased based on the
following incremental doses: 25 mg PO TID,
50 mg PO BID, 50 mg PO TID. Dose increments
were communicated with the primary care
physician, and the highest dose of 50 mg PO
TID was only used if explicitly approved by the
patient’s primary care physician. All patients
were maintained on the medication for at least
three months, and electrolytes were evaluated
every 3 months.
If subretinal fluid resolved, the injection
interval was extended. At each visit, patients
had a complete eye exam, OCT with enhanced
depth imaging, and an evaluation of side effects
and tolerance of the medication.
Data analysis included a review of
demographic data and detailed analysis of
OCT images, including documentation of
subretinal fluid, central macular thickness,
pigment epithelial detachment height,
presence of a pachychoroid, and presence of
shagginess of the photoreceptor outer layer.
Pachychoroid was defined as increased
choroidal thickness, as would be expected for
modifications of age and myopia based on
SD-OCT images. Shaggy photoreceptors were
defined as elongated with a slightly stippled
edge, and were clearly distinct from the normal
photoreceptor junction. In data analysis,
patients were divided into groups with (group
Ophthalmol Ther
A) and without (group B) moderate-large
pigment epithelial detachments (PEDs),
defined as greater than 350 lm in height by
SD-OCT imaging. The T test was used to
determine statistical significance.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent to be included in the
study was obtained from all patients.
RESULTS
Twenty-three patients were included in the
study. Mean age was 64.6 years, and 12
patients were female (52.2%), 11 were male
(47.8%). 10 of the 23 patients were in group A
(large PEDs), and this group did not show a
significant reduction in SRF or an extension of
the injection interval. 13 of the 23 patients were
in group B and had predominantly chronic
subretinal fluid with an absence of
medium-large pigment epithelial detachments.
In group B, mean initial CMT was 305.3 lm and
mean final CMT was 240.6 lm (p\0.05). Mean
initial injection interval was 40.25 days and
mean final injection interval was 54.61 days
(p\0.05). The mean extension of the injection
interval in this group was 14.36 days.
An overall optimal response was noted in
patients that had a shaggy photoreceptor outer
layer, were pachychoroid for age, and had an
absence of moderate-large pigment epithelial
detachments. 8 of the 13 patients in group B
had all these characteristics. In this subgroup,
mean initial CMT was 319.4 lm and mean final
CMT was 236.1 lm. The mean initial injection
interval was 39.5 days and the mean final
injection interval was 60.7 days (p\0.05), for
a mean extension of the injection interval in
this group of 21.2 days.
Two cases are presented of patients from
group B. Case 1 (Fig. 1a–e) was a 72-year-old
female who presented with 20/200 vision and
typical findings of neovascular wet AMD with
minimal subretinal fluid and significant cystoid
macular edema due to evident choroidal
neovascularization on FA. After three months of
serial intravitreal bevacizumab, her vision
improved to 20/60 and her significant CME had
largely resolved, with some persistence of trace
subretinal fluid. At month 6, all of her CME had
resolved, the subretinal fluid had slightly
increased, some shagginess of the photoreceptor
Fig. 1 a Month 0: VA: 20/200. b Month 3: after
3 months bevacizumab, VA: 20/60. c Month 6: after
6 months bevacizumab, VA: 20/70. d Month 9: after
6 months bevacizumab, 3 months aﬂibercept, VA: 20/70.
e Month 11: after 2 months eplerenone, VA: 20/50
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outer layer had become evident, and vision had
decreased to 20/70. At this point, the patient was
switched to aflibercept, and after three months of
serial aflibercept, the patient presented a further
increase in subretinal fluid and shagginess of the
photoreceptor outer layer, with vision remaining
at 20/70. At this point, the patient was started on
oral eplerenone 25 mg PO BID, and two months
later all the subretinal fluid had resolved, and
vision had improved to 20/50.
Case 2 (Fig. 2a–e) was an 80-year-old female.
She initially presented with significant CME
and SRF with a BCVA of 20/150. After three
months of bevacizumab, all the CME had
resolved, and vision had improved to 20/80,
but she had persistent subretinal fluid and a
shaggy photoreceptor outer layer, so she was
switched to aflibercept. After 6 months of
aflibercept, there was only a very slight
reduction in pigment epithelial detachment
subretinal fluid height, and oral eplerenone
was initiated. After 2 months of oral
eplerenone, most of the subretinal fluid had
resolved, pigment epithelial detachment height
had decreased further, and vision had improved
to 20/40. One month later (3 months after
starting oral eplerenone), all subretinal fluid
had resolved, and vision remained at 20/40.
DISCUSSION
Intravitreal anti-VEGF agents have become the
standard of care for wet AMD. There is a small
percentage of patients that have refractory
subretinal fluid despite serial anti-VEGF
treatments. While some of these patients
respond to switching anti-VEGF agents, in
some cases chronic SRF can persist [1, 2].
Photodynamic therapy (PDT) has been
described as successful in some of these cases,
even in the absence of any identification of
polypoidal choroidal vasculopathy or true CSR,
and the etiology has been proposed as a
‘‘secondary sick RPE syndrome’’ [2, 3].
In this series, oral eplerenone demonstrated
efficacy as an adjunct to intravitreal anti-VEGF
in cases of presumed neovascular AMD with
chronic subretinal fluid. The optimal response
to eplerenone was evident in patients with an
absence of moderate-large pigment epithelial
detachments and with pachychoroid and a
shaggy photoreceptor outerlayer present. In
this subset of patients, SRF resolved
completely, and they experienced an
extension of their injection interval of
approximately 3 weeks. Given recent data
suggesting that serial anti-VEGF may
contribute to geographic atrophy progression
in some cases, this data is noteworthy [8].
Fig. 2 a Month 3: after 3 months bevaciuzmab, VA:
20/80. b Month 9: after 3 months bevacizumab and
6 months aﬂibercept, VA: 20/70. c Month 11: after
2 months eplerenone, VA: 20/40. d Month 12, after
3 months eplerenone, VA: 20/40
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It is interesting that patients with these
characteristics responded optimally to the
medication in this study, as each of these
findings have been independently correlated
as anatomic findings in CSCR. Patients with
CSCR tend to have single or multiple discrete
low-lying PEDs, if they are present [9]. A
pachychoroid, clearly identifiable as an
abnormal increase in choroidal thickness on
enhanced-depth OCT imaging, has been
described as a consistent feature of CSCR [10].
‘‘Shaggy’’ photoreceptor outer layer segments
have also been described as a key anatomic
feature of CSCR [11].
This anatomic overlay begs the question of
whether a deeper overlap of wet AMD and CSCR
exists in some patients than previously realized.
The demographic breakdown in the present
study does not classically point to one typical of
patients with CSCR, given a relatively
equivalent breakdown of sex and a mean age
that is much higher than average for CSCR. We
also did not find evidence of a true sick RPE
syndrome in these patients, as initial or repeat
ICG did not show evidence of a true diffusely
abnormal choroidal circulation. It is possible
that these patients develop a secondary focal
reactive RPE dysfunction that leads to a
CSCR-type response.
Limitations of this study include its
retrospective nature and the limitation of our
ability to make inferences until a randomized
controlled trial is completed.
CONCLUSION
In this study, oral eplerenone treatment
demonstrated efficacy as an adjunct to the
treatment of neovascular AMD, as
demonstrated by statistically significant
decreases in subretinal fluid and central
macular thickness and the extension of the
anti-VEGF injection interval in select patients.
Further research is needed to better elucidate
the precise role of mineralocorticoid
antagonists in neovascular AMD.
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